{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T20:45:22Z","timestamp":1758055522483,"version":"3.44.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.chest.2022.06.032","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T04:07:09Z","timestamp":1670299629000},"page":"1231-1232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravitreal Bevacizumab for Retinopathy of Prematurity"],"prefix":"10.1016","volume":"162","author":[{"given":"Ignacio","family":"Oulego-Erroz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Alonso-Ojembarrena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9902","key":"10.1016\/j.chest.2022.06.032_bib1","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"Hellstr\u00f6m","year":"2013","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.chest.2022.06.032_bib2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1056\/NEJMoa1514212","article-title":"Outcomes of two trials of oxygen-saturation targets in preterm infants","volume":"374","author":"Tarnow-Mordi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.chest.2022.06.032_bib3","first-page":"CD009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.chest.2022.06.032_bib4","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S2352-4642(21)00195-4","article-title":"2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial","volume":"5","author":"Marlow","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"6","key":"10.1016\/j.chest.2022.06.032_bib5","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/s41372-020-00884-9","article-title":"Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis","volume":"41","author":"Kaushal","year":"2021","journal-title":"J\u00a0Perinatol"},{"issue":"1","key":"10.1016\/j.chest.2022.06.032_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/978-1-60761-500-2_21","article-title":"Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease","volume":"661","author":"Abman","year":"2010","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"10.1016\/j.chest.2022.06.032_bib7","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1164\/rccm.201707-1371OC","article-title":"Anti-sFlt-1 therapy preserves lung alveolar and vascular growth in antenatal models of bronchopulmonary dysplasia","volume":"197","author":"Wallace","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2022.06.032_bib8","first-page":"121","article-title":"Acute and chronic effects of intravitreal bevacizumab on lung biomarkers of angiogenesis in the rat exposed to neonatal intermittent hypoxia","volume":"47","author":"Duggan","year":"2021","journal-title":"Exp Lung Res"},{"issue":"3","key":"10.1016\/j.chest.2022.06.032_bib9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/01902148.2017.1306897","article-title":"Intravitreal bevacizumab alters type IV collagenases and exacerbates arrested alveologenesis in the neonatal rat lungs","volume":"43","author":"Valencia","year":"2017","journal-title":"Exp Lung Res"},{"issue":"6","key":"10.1016\/j.chest.2022.06.032_bib10","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.chest.2022.06.017","article-title":"Intravitreal bevacizumab is associated with prolonged ventilatory support in preterm infants with bronchopulmonary dysplasia","volume":"162","author":"Huang","year":"2022","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2022.06.032_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40272-020-00433-z","article-title":"Ranibizumab: a review in retinopathy of prematurity","volume":"23","author":"Lee","year":"2021","journal-title":"Paediatr Drugs"},{"issue":"10208","key":"10.1016\/j.chest.2022.06.032_bib12","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369222012119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369222012119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:44:30Z","timestamp":1757925870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369222012119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0012369222012119"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2022.06.032","relation":{},"ISSN":["0012-3692"],"issn-type":[{"type":"print","value":"0012-3692"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravitreal Bevacizumab for Retinopathy of Prematurity","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2022.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2022.06.017","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}